Citigroup reiterated AstraZeneca PLC (LON:AZN) to Buy in a statement released earlier today.
- Updated: September 24, 2016
Citigroup has reiterated AstraZeneca PLC (LON:AZN) to Buy in a report released on 9/23/2016.
Previously on 9/21/2016, Jefferies International released a statement about AstraZeneca PLC (LON:AZN) held steady the target price at 5,800.00GBX. At the time, this indicated a possible upside of 0.13%.
Just yesterday AstraZeneca PLC (LON:AZN) traded 0.25% higher at 5,140.50GBX. AstraZeneca PLC’s 50-day average is 5,029.35GBX and its two hundred day average is 4,367.23GBX. With the last close up 18.38% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 1,872,104 shares of the stock traded hands, down from an average trading volume of 2,790,240
See Chart Below
AstraZeneca PLC has a 52 week low of 3,680.00GBX and a 52 week high of 5,505.00GBX with a PE ratio of 29.54 AstraZeneca PLC’s market capitalization is currently 0 GBX.
In addition to Citigroup reporting its target price, a total of 29 firms have reported on the stock. The consensus target price is 61.96GBX with 4 firms rating the stock a strong buy, 14 firms rating the stock a buy, 13 firms rating the stock a hold, 2 firms rating the stock a underperform, and finally 1 firm rating the stock a sell.
About AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.